Explore

Trendline Trendline
Prokarium's ZH9 Shows Promising Results in Bladder Cancer Trial

Prokarium's ZH9 Shows Promising Results in Bladder Cancer Trial

Prokarium's ZH9 Shows Promising Results in Bladder Cancer Trial
Trendline Trendline
MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial

MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial

MSD's Sac-TMT Shows Promise in Phase 3 Endometrial Cancer Trial
Trendline Trendline
Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support
Trendline Trendline
Aspera Biomedicines Launches ADAR1p150 Crystallization Experiment to ISS for Cancer Research

Aspera Biomedicines Launches ADAR1p150 Crystallization Experiment to ISS for Cancer Research

Aspera Biomedicines Launches ADAR1p150 Crystallization Experiment to ISS for Cancer Research
Trendline Trendline
Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis
Trendline Trendline
Merck's Sac-TMT Shows Promise in Improving Survival for Endometrial Cancer Patients

Merck's Sac-TMT Shows Promise in Improving Survival for Endometrial Cancer Patients

Merck's Sac-TMT Shows Promise in Improving Survival for Endometrial Cancer Patients
Trendline Trendline
Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Merck's Sacituzumab Tirumotecan Shows Promise in Endometrial Cancer Trial

Merck's Sacituzumab Tirumotecan Shows Promise in Endometrial Cancer Trial

Merck's Sacituzumab Tirumotecan Shows Promise in Endometrial Cancer Trial
Trendline Trendline
Merck's TroFuse-005 Trial Achieves Key Endpoints in Advanced Endometrial Cancer Treatment

Merck's TroFuse-005 Trial Achieves Key Endpoints in Advanced Endometrial Cancer Treatment

Merck's TroFuse-005 Trial Achieves Key Endpoints in Advanced Endometrial Cancer Treatment
Trendline Trendline
Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal